JPMorgan has released a research report indicating that MEDBOT-B's (02252) preliminary fiscal 2025 performance forecast is higher than market expectations but lower than the bank's own projections. Consequently, the bank has slightly adjusted its target price from HK$42 to HK$41, maintaining an "Overweight" rating and its status as the top pick in the Chinese medical technology sector. JPMorgan has lowered its sales forecast for MEDBOT-B's 2025 fiscal year by 12%, while raising its forecasts for the current and following years by 3% to 4%. The bank continues to believe the company is a strong Chinese competitor in the global surgical robotics field and expects it to sustain growth overseas, particularly in regions such as Europe, Latin America, and Asia-Pacific. Simultaneously, the report identifies the stock's next potential catalysts as the announcement of potential cumulative orders and its profit performance. JPMorgan further noted that based on MEDBOT-B's preliminary fiscal 2025 results, it has revised down the group's last year sales forecast from 646 million yuan to 567 million yuan, primarily due to lower-than-expected Skywalker sales. Nevertheless, the bank continues to expect the company to achieve breakeven this year and has raised its current year sales forecast from 1.356 billion yuan to 1.416 billion yuan.